Gadolinium and nephrogenic systemic fibrosis: an update
- 22 October 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pediatric Nephrology
- Vol. 29 (10), 1927-1937
- https://doi.org/10.1007/s00467-013-2636-z
Abstract
No abstract availableKeywords
This publication has 89 references indexed in Scilit:
- Nephrogenic systemic fibrosis: Review of 408 biopsy-confirmed casesIndian Journal of Dermatology, 2011
- Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: Critical review of the literature and UK experienceJournal of Magnetic Resonance Imaging, 2009
- Quality Initiatives MR Imaging in Patients at Risk for Developing Nephrogenic Systemic Fibrosis: Protocols, Practices, and Imaging Techniques to Maximize Patient SafetyRadioGraphics, 2009
- How to estimate GFR in childrenNephrology Dialysis Transplantation, 2008
- Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical reviewBioMetals, 2008
- Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosisThe Journal of Pathology, 2007
- Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosisJournal of the American Academy of Dermatology, 2007
- Biochemical safety profiles of gadolinium‐based extracellular contrast agents and nephrogenic systemic fibrosisJournal of Magnetic Resonance Imaging, 2007
- Nephrogenic Systemic FibrosisArchives of Dermatology, 2007
- Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis—Setting the Record StraightSeminars in Arthritis and Rheumatism, 2006